LINTEX
920106
LINGOOD
833284
NTGEC
870436
4
CG MED EQUIP.
838810
5
Jiayu Holding
300117
US Stock MarketDetailed Quotes
CMMB Chemomab Therapeutics
- 1.680
- +0.060+3.70%
Close Feb 28 16:00 ET
- 1.670
- -0.010-0.60%
Post 20:01 ET
31.68MMarket Cap-1.79P/E (TTM)
1.710High1.620Low42.55KVolume1.620Open1.620Pre Close70.88KTurnover0.36%Turnover RatioLossP/E (Static)18.86MShares2.55052wk High1.94P/B19.86MFloat Cap0.57952wk Low--Dividend TTM11.82MShs Float184.000Historical High--Div YieldTTM5.56%Amplitude0.420Historical Low1.665Avg Price1Lot Size
Chemomab Therapeutics News
Chemomab Therapeutics Analyst Ratings
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $7
Analysts Are Bullish on Top Healthcare Stocks: Chemomab Therapeutics (CMMB), Blueprint Medicines (BPMC)
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $11
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Cuts Target Price to $11
Chemomab Therapeutics Analyst Ratings
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $9
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Chemomab Therapeutics (CMMB) Gets a Buy From Oppenheimer
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $4
Roth MKM Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $9
Oppenheimer Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Raises Target Price to $13
Chemomab Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)
Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)
Chemomab Therapeutics Analyst Ratings
Chemomab Therapeutics Analyst Ratings
Trending Stocks
Discussing
Widespread uptick! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. Chinese stocks l
Moomoo News Global
Feb 24 22:30
Chinese Stocks' Wild Rally Hits Pause? Wall Street Still Bets Big on Favorites